1. Clinical Overview
Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine. At the 0.2mg strength, it is primarily indicated for the management of moderate to severe acute pain. It is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist, offering a unique pharmacological profile with a ceiling effect on respiratory depression, making it potentially safer than full agonists in certain contexts. In India, it is a critical component of pain management protocols and is also used in opioid dependence treatment at higher doses.
| Onset | Duration | Bioavailability |
|---|---|---|
| Sublingual: 30-60 minutes; Intramuscular/Intravenous: 15 minutes | 6 to 8 hours (analgesic effect); up to 24-72 hours for receptor occupancy | Sublingual: 30-55%; Intramuscular: High (approx. 70-90%) |
2. Mechanism of Action
Buprenorphine binds with high affinity and slow dissociation to mu-opioid receptors (MOR) in the central nervous system, acting as a partial agonist. This provides effective analgesia while having a lower intrinsic activity (efficacy) compared to full agonists like morphine. It also acts as an antagonist at the kappa-opioid receptor, which may contribute to its analgesic effect and lower propensity for dysphoria and psychotomimetic effects.
3. Indications & Uses
- Management of moderate to severe acute pain (e.g., post-operative pain, trauma)
- Opioid dependence maintenance therapy (at higher doses, typically 2mg, 4mg, 8mg, 16mg)
4. Dosage & Administration
Adult Dosage: For Acute Pain (Sublingual/IM/IV): 0.2-0.4 mg every 6 to 8 hours as needed for pain. Dose titration should be individualized. Maximum single dose for acute pain is typically 0.6 mg.
Administration: Sublingual Tablet: Place under the tongue until completely dissolved. Do not chew, swallow, or move the tablet. Avoid eating or drinking until tablet is fully dissolved. Intramuscular/Intravenous: Administer slowly. For IV, can be given as a slow injection over at least 2 minutes. Rotate IM injection sites.
5. Side Effects
Common side effects may include:
- Nausea
- Vomiting
- Constipation
- Dizziness
- Sedation/somnolence
- Headache
- Sweating
- Dry mouth
- Miosis (pinpoint pupils)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Benzodiazepines (e.g., Alprazolam, Diazepam) | Profound sedation, respiratory depression, coma, and death | Major |
| Other CNS Depressants (Alcohol, Barbiturates, Sedative-hypnotics) | Additive CNS and respiratory depression | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Clarithromycin, Grapefruit juice) | Increased buprenorphine plasma levels, risk of toxicity | Moderate |
| CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased buprenorphine plasma levels, reduced efficacy, potential withdrawal | Moderate |
| Full Opioid Agonists (e.g., Morphine, Fentanyl, Methadone) | Buprenorphine may block effects or precipitate withdrawal due to high receptor affinity | Major |
| MAO Inhibitors (e.g., Phenelzine, Selegiline) | Risk of serotonin syndrome or exaggerated opioid effects | Major |
| Serotonergic Drugs (SSRIs, SNRIs, TCAs, Tramadol) | Increased risk of serotonin syndrome | Moderate |
| Anticholinergics | Increased risk of urinary retention and constipation | Moderate |
| Antihypertensives | Potentiation of hypotensive effects | Moderate |
7. Patient Counselling
- DO take exactly as prescribed. Do not increase dose or frequency.
- DO allow sublingual tablet to dissolve completely under the tongue. Do not chew or swallow.
- DO inform all your doctors and dentists that you are taking this medication.
- DO store securely out of reach of children and others.
- DONT consume alcohol or sleep-inducing medications (without doctor's advice).
- DONT drive or operate heavy machinery until you know how it affects you.
- DONT stop taking suddenly if used long-term; taper under medical supervision to avoid withdrawal.
8. Toxicology & Storage
Overdose: Pinpoint pupils, respiratory depression (may be less severe than with full agonists due to ceiling effect), somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, hypotension, circulatory collapse, cardiac arrest, death.
Storage: Store at room temperature (15-30°C). Protect from light and moisture. Keep in the original blister pack or container. Keep locked and out of sight and reach of children and others. Dispose of unused medication properly as per pharmacy guidelines; do not flush.